Le Lézard
Classified in: Science and technology

Eddy Smart Home Solutions Ltd. (formerly Aumento Capital VIII Corp.) Announces its Intention to Restate its Financial Statements and MD&A


NO IMPACT ON CASHFLOWS AND BUSINESS OPERATIONS

TORONTO, Aug. 19, 2022 /CNW/ - Eddy Smart Home Solutions Ltd. (formerly Aumento Capital VIII Corp.) ("Eddy" or the "Company") (TSXV: EDY) today announced that after revisiting its interpretation and application of certain technical accounting standards related to non-cash consideration provided to a developer and customer (the "Developer") through an amended exclusive supplier agreement dated December 15, 2021 (the "Addendum"), it will restate and refile its consolidated financial statements for the year ended December 31, 2021, which were originally filed on SEDAR on May 6, 2022, the condensed consolidated interim financial statements for the three months ended March 31, 2022, which were originally filed on May 30, 2022, relevant comparative periods, and the related management's discussion and analysis ("MD&A") for those periods (collectively, the "Affected Disclosures").

On December 15, 2021, the Eddy Smart Home Solutions Inc. entered the Addendum with the Developer to amend an exclusive supplier agreement originally entered into in January 2019. Pursuant to the Addendum, Eddy Smart Home Solutions Inc. was obligated to issued to the Developer 1,453,767 common shares and 1,900,000 common share purchase warrants of the Company (the "RTO Securities") contingent on the successful completion of the Company's reverse takeover transaction (the "RTO Transaction") which was achieved on January 12, 2022. In addition, the Company agreed to issue 750,000 common shares of the Company (together with the RTO Securities, the "Securities"), contingent on the Developer providing contracts to the Company for at least 12,500 units at the Developer's condominium projects.

The board of directors of Eddy has determined that the Affected Disclosures are required to be restated because of the magnitude of the expected impact. For the year ended December 31, 2021, the impact is expected to be isolated to the consolidated statement of financial position, increasing prepaid expenses and contributed surplus by approximately $1.6 million. For the three months ended March 31, 2022, the impact to prepaid expenses is expected to slightly less than the December 31, 2021 impact, with a further impact of an expected reduction to general and administrative expenses and deficit of approximately $1.55 million, along with immaterial adjustments to contributed surplus and revenue.

With the exception of potential cash flows received through the exercise of the warrants, the restatement is not expected to have an impact on the past, current or future cash flows of the Company.

Management has determined that the application of the applicable IFRS standards was done incorrectly with respect to how the Securities were measured at the date of the amendment and recognized once issued upon completion of the RTO Transaction.

Travis Allan, Chief Executive Officer and Director of Eddy, said, "We take seriously our obligation to provide accurate financial statements and we have acted accordingly in providing this information".

The Company intends to file its restated financial statements and the corresponding management discussion and analysis on or about September 30, 2022.

About Eddy

Eddy is a North American provider and developer of residential and commercial smart water metering products and monitoring services, helping property owners protect, control, and conserve water usage by combining water sensing devices with behavioural learning software. For more detail on the Company's products or corporate information please visit www.eddysolutions.com.

Forward-Looking Information and Statements

This news release contains forward-looking statements within the meaning of applicable securities laws including, among others, statements concerning our objectives, our strategies to achieve those objectives, our performance, as well as statements with respect to management's beliefs, estimates, and intentions, and similar statements concerning anticipated future events, results, circumstances, performance, or expectations that are not historical facts. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "outlook", "objective", "may", "will", "expect", "intent", "estimate", "anticipate", "believe", "should", "plans", or "continue", or similar expressions suggesting future outcomes or events. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management. Forward looking information in this news release includes information regarding the filing of the restated financial statements and the expected changes that will be included therein. These statements are not guarantees of future performance and are based on our estimates and assumptions that are subject to risks and uncertainties, including those described under the heading "Risk Factors" in the Company's filing statement dated January 6, 2022 (a copy of which can be obtained at www.sedar.com), which could cause our actual results and performance to differ materially from the forward-looking statements contained in this news release.

All forward-looking statements in this news release are qualified by these cautionary statements. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Eddy Smart Home Solutions Ltd.


These press releases may also interest you

at 07:05
Aldeyra Therapeutics, Inc. (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the clinical development plan intended to enable...

at 07:05
Mythic Therapeutics, a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, announced that George Eliades, Ph.D., has joined the...

at 07:05
WorkForce Software, the #1 rated workforce management solution for large employers, is pleased to announce the appointment of Marc Havercroft as Senior Vice President of International Sales. In this role, Havercroft will lead the company's...

at 07:05
Seres Therapeutics, Inc. ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on March 25, 2024, the Compensation and Talent Committee of Seres' board of directors granted inducement equity grants covering an...

at 07:05
Fox Lake Grade School District 114 today announced a partnership with Varsity Tutors for Schools, a Nerdy company and the leading platform for live online tutoring, to provide its Stanton Middle School students with access to the Varsity Tutors for...

at 07:05
Gilead Sciences, Inc. and Xilio Therapeutics, Inc. today announced an exclusive license agreement to develop and commercialize Xilio's Phase 1 tumor-activated IL-12 program, XTX301. Xilio Therapeutics is a clinical-stage biotechnology company...



News published on and distributed by: